Source Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN, USA.

BACKGROUND & AIMS: The relative frequency of non-alcoholic steatohepatitis (NASH) as an indication for liver transplantation, and comparative outcomes following transplantation, are poorly understood.

METHODS: We analyzed the scientific registry of transplant recipients (SRTR) for primary, adult, liver transplant recipients, from 2001 to 2009.

RESULTS: From 2001 to 2009, 35781 patients underwent primary liver transplantation, including 1959 for whom NASH was the primary or secondary indication. The percentage of patients undergoing liver transplantation for NASH increased from 1.2% in 2001 to 9.7% in 2009. NASH is now the third most common indication for liver transplantation in the United States. No other indication for liver transplantation increased in frequency during the study period. Compared with other indications for liver transplantation, recipients with NASH are older (58.5 +/- 8.0 y vs 53.0 +/- 8.9 y;P<.001), have a larger body mass index (BMI> 30) (63% vs 32; P<.001), are more likely to be female (47% vs 29%;P<.001), and have a lower frequency of hepatocellular carcinoma (12% vs 19%;P<.001). Survival at 1 and 3 y after liver transplantation for NASH were 84% and 78%, respectively, compared with 87% and 78% for other indications (P=.67). Patient and graft survival for liver recipients with NASH were similar to values for other indications, after adjusting for level of creatinine, sex, age, and BMI.

CONCLUSIONS: NASH is the third most common indication for liver transplantation in the United States and is on a trajectory to become the most common. Outcomes for patients undergoing liver transplantation for NASH are similar to those for other indications.